Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

22 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 9, 2019

65 Biggest Movers From Yesterday

Benzinga.com  January 8, 2019

42 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  January 7, 2019

Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018

Business Wire January 7, 2019

Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2019

Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape

GlobeNewswire December 26, 2018

Le CHMP émet un avis positif concernant la nouvelle indication des comprimés de Rubraca®▼ (rucaparib), de Clovis Oncology, en tant que traitement d’entretien pour les femmes atteintes d’un cancer ovarien récurrent

Business Wire December 14, 2018

26 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  December 14, 2018

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer

Business Wire December 13, 2018

Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies

PR Newswire December 6, 2018

Explosion of Latest Clinical Studies and Results Reinvigorating Immunotherapy Market

PR Newswire December 4, 2018

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  December 4, 2018

Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca®

Business Wire December 4, 2018

46 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  December 3, 2018

Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035

Business Wire November 20, 2018

Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference

Business Wire November 7, 2018

75 Biggest Movers From Yesterday

Benzinga.com  November 7, 2018

76 Biggest Movers From Yesterday

Benzinga.com  November 2, 2018

82 Biggest Movers From Yesterday

Benzinga.com  November 1, 2018

66 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  October 31, 2018